SALANI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 521
EU - Europa 434
AS - Asia 133
AF - Africa 79
Totale 1.167
Nazione #
US - Stati Uniti d'America 521
IT - Italia 189
SE - Svezia 130
SG - Singapore 87
CI - Costa d'Avorio 51
BG - Bulgaria 35
AT - Austria 27
GB - Regno Unito 24
NG - Nigeria 18
CN - Cina 14
IN - India 14
SN - Senegal 10
DE - Germania 8
PL - Polonia 8
HK - Hong Kong 7
VN - Vietnam 6
IR - Iran 3
BE - Belgio 2
CH - Svizzera 2
FI - Finlandia 2
FR - Francia 2
RO - Romania 2
CZ - Repubblica Ceca 1
IE - Irlanda 1
JP - Giappone 1
LK - Sri Lanka 1
UA - Ucraina 1
Totale 1.167
Città #
Chandler 90
Fairfield 54
Abidjan 51
New York 42
Milan 36
Ashburn 35
Sofia 35
Seattle 30
Singapore 29
Florence 27
Vienna 27
Pisa 20
Woodbridge 20
London 19
Lagos 18
Lawrence 17
Princeton 17
Cambridge 16
Wilmington 15
Kent 12
Hyderabad 11
Ogden 11
Dakar 10
Medford 10
Houston 9
Ann Arbor 7
Beijing 7
Hong Kong 7
Warsaw 7
Los Angeles 6
Norwalk 5
Rome 5
Vicopisano 5
Castiglione Chiavarese 4
Frankfurt am Main 4
Piombino 4
San Diego 4
Bremen 3
Center 3
Livorno 3
Massa 3
Santa Croce sull'Arno 3
Shanghai 3
Turin 3
Boardman 2
Bologna 2
Brussels 2
Ebikon 2
Farra di Soligo 2
Forlì 2
Lappeenranta 2
Lucca 2
Messina 2
Padova 2
Philadelphia 2
Romainville 2
Serra 2
Sesto San Giovanni 2
Barletta 1
Carugate 1
Casaleone 1
Changsha 1
Ciampino 1
Dublin 1
Formigine 1
Fulham 1
Garbagnate Milanese 1
Hangzhou 1
Islington 1
Kashan 1
Minerbio 1
Minneapolis 1
New Delhi 1
North Charleston 1
Olomouc 1
Pietrasanta 1
Redmond 1
Redwood City 1
Rosignano Marittimo 1
Southwark 1
Stuttgart 1
Venezia 1
Verona 1
Viareggio 1
Vicenza 1
Washington 1
Yokohama 1
Totale 804
Nome #
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 110
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 90
Invasive Meningococcal Disease due to group C N. meningitidis ST11 (cc11): The Tuscany cluster 2015–2016 77
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 75
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 69
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 67
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 60
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 60
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 51
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 44
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 44
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 42
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 40
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 40
In Reply 40
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 39
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 29
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 28
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 27
Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 25
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 23
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 22
Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 21
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 19
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 15
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 13
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 12
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 12
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 11
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 10
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 7
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 7
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 6
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 5
Totale 1.240
Categoria #
all - tutte 5.883
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.883


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202076 3 9 0 4 4 5 9 9 8 5 17 3
2020/202192 6 2 4 5 6 20 3 5 11 8 10 12
2021/2022193 0 1 3 6 40 40 4 2 17 12 22 46
2022/2023452 47 69 33 15 50 58 6 35 91 2 37 9
2023/2024415 21 40 41 25 58 38 64 16 5 17 39 51
2024/202512 12 0 0 0 0 0 0 0 0 0 0 0
Totale 1.240